EX-10.28-K·CIK 1860657·0001213900-26-121103

Letter Agreement, Dated November 12, 2026, by and Between Allarity Therapeutics, Inc. and Streeterville Capital, Llc

View original filing on SEC EDGAR → ·  seen Nov 17, 2026, 09:40 EST

Exhibit 10.2

** **

STREETERVILLE CAPITAL, LLC

November 12, 2026

Allarity Therapeutics, Inc.

Attn: Thomas Jensen

tjensen@allarity.com

Re: Conditional Consent to Future Use of ATM

Dear Thomas:

This letter agreement (this “Letter Agreement”) is entered into by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Allarity Therapeutics, Inc., a Delaware corporation (“Company”), in connection with Company’s Certificate of Designation of Preferences and Rights of Series B Preferred Stock (the “Series B Certificate”). Reference is also made to that certain Exchange Agreement by and between Investor and Company of even date herewith (the “Exchange Agreement”). Capitalized terms used but not otherwise defined herein will have the meanings ascribed to such terms in the Series B Certificate. Investor and Company hereby agree as follows:

1. Conditional Consent to Use of ATM.

(a) Investor hereby grants its consent for Company to sell shares of its Common Stock under any future at-the-market (ATM) trading facility, notwithstanding Section 10(e) of the Series B Certificate, subject to the terms of this Section 1. The foregoing consent may be revoked by Investor at any time by delivering written notice of such to Company.
(b) For each week that Company sells Common Shares under its ATM, Company shall pay Investor, by wire transfer of immediately available funds, an amount equal to thirty-three percent (33%) of the net proceeds from all sales settled during that week (each, a “Sweep Payment”).
(c) Investor may elect, by written notice delivered at any time and from time to time, to apply any Sweep Payment, in whole or in part, to either or both of the following:
i. redemption of shares of Series B Stock held by Investor, at the Redemption Price set forth in the Series B Certificate; and
ii. repayment of the outstanding balance of the Note (as defined in the Exchange Agreement), as elected by Investor.
(d) If no election is in effect, unless the redemption described in clause (i) is not permitted by applicable law or the Series B Certificate, the Sweep Payment shall be applied under clause (i). Once the Note is paid in full or Investor no longer owns and shares of Series B Stock, the entire Sweep Payment shall be applied to the other.
(e) Upon Investor’s request, if any sales were made pursuant to the ATM during the preceding week, Company shall provide Investor with a report detailing the aggregate number of shares sold and gross proceeds received from such sales during such week.
(f) Any failure to make a Sweep Payment when due shall be considered an event of default under the Note and the Series B Certificate.
(g) This consent is limited to the matters expressly set forth herein. It does not waive any other provision of any other agreement between the parties or any default thereunder.

2. B Note Exchanges. The parties agree that for purposes of Section 1.7 of the Purchase Agreement (as defined in the Exchange Agreement), the value of the Series B Stock held by Investor (calculated as number of shares held by Investor multiplied by the Stated Value) will be included in the calculation of the aggregate outstanding balance of all A Notes in connection with Note Exchanges.

3. Form 8-K Disclosure. Company agrees to promptly disclose on Form 8-K its then-current number of outstanding Common Shares each time the number of outstanding Common Shares increases by five percent (5%) or more as a result of issuances of Common Shares pursuant to the Company’s ATM.

4. Conflict. In the event of a conflict between the terms and conditions contained in this Letter Agreement and those contained in the Series B Certificate, the terms and conditions contained herein shall control.

5. Transaction Document; Incorporation of Purchase Agreement Provisions. The provisions of Section 8 of the Purchase Agreement including without limitation the governing law, Arbitration Provisions (as defined the Purchase Agreement), venue, notice, fees and expenses, waiver of jury trial, and severability provisions thereof, are hereby incorporated herein by reference and shall apply to this Letter Agreement, mutatis mutandis, as if fully set forth herein, and each reference therein to “this Agreement” shall be deemed to refer to this Letter Agreement. Without limiting the foregoing, this Letter Agreement and all questions concerning its construction, validity, interpretation, enforcement and performance shall be governed by the internal laws of the State of Utah, without regard to any choice-of-law or conflict-of-law provision or rule that would cause the application of the laws of any other jurisdiction, and any dispute arising out of or relating to this Letter Agreement shall be resolved in accordance with the Arbitration Provisions.

6. Assignment; Binding upon Successors and Assigns. Company may not assign any of its rights or obligations hereunder without the prior written consent of Investor. Investor may assign its rights and obligations hereunder, in whole or in part, without the consent of Company. This Letter Agreement will be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

2

7. Amendment and Waivers. Any term or provision of this Letter Agreement may be amended and the observance of any term of this Letter Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a writing signed by the parties hereto. The waiver by either party of any breach hereof or default in the performance hereof will not be deemed to constitute a waiver of any other default or any succeeding breach or default.

8. Entire Agreement. This Letter Agreement contains the entire understanding between the parties hereto with respect to the subject matter hereof and supersedes any prior understandings, agreements or representations, written or oral, relating to the subject matter hereof, other than the other Exchange Documents (as defined in the Exchange Agreement) and the Transaction Documents (as defined in the Exchange Agreement), which remain in full force and effect and are hereby ratified and confirmed. Except as expressly set forth herein, nothing in this Letter Agreement shall be deemed a waiver or modification of any right or remedy of Investor under the Exchange Documents or the Transaction Documents, all of which are expressly reserved.

9. Counterparts. This Letter Agreement may be executed in counterparts, each of which when executed and delivered shall be deemed an original and all of which, taken together, shall constitute the same agreement. This Letter Agreement may be executed by electronic signature, which shall be considered legally binding for all purposes.

10. Further Assurances. Each party to this Letter Agreement agrees to perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Letter Agreement.

11. Company Representations. Company represents and warrants to Investor that it has all requisite corporate power and authority to execute, deliver and perform this Letter Agreement, and this Letter Agreement has been duly authorized, executed and delivered by Company and constitutes its valid and binding obligation, enforceable against Company in accordance with its terms.

[Remainder of page intentionally left blank; signature page to follow]

3

IN WITNESS WHEREOF, Investor and Company have duly executed and delivered this Letter Agreement to be effective as of the date first set forth above.

** ** INVESTOR:
STREETERVILLE CAPITAL, LLC
By: /s/ John Fife
John Fife, President
ACCEPTED AND AGREED:
COMPANY:
ALLARITY THERAPEUTICS, INC.
By: /s/ Thomas Jensen
Thomas Jensen, Chief Executive Officer

[Signature Page to Letter Agreement]

Back to all agreements